Organoid development and applications in gynecological cancers: the new stage of tumor treatment

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: Jan. 16, 2025

Gynecologic cancers (GCs), including cervical cancer (CC), ovarian (OC), endometrial (EC), as well vulvar and vaginal cancers, represent major health threats to women, with increasing incidence rates observed globally. Conventional treatments, such surgery, radiation therapy, chemotherapy, are often hindered by challenges drug resistance recurrence, contributing high mortality rates. Organoid technology has emerged a transformative tool in research, offering vitro models that closely replicate the tumor cell architecture heterogeneity of primary cancers. Tumor-derived organoids preserve histological molecular characteristics original tumors, making them invaluable for studying biology, pathways, immune microenvironment. Furthermore, play crucial role biomarker discovery, screening, development personalized therapeutic strategies. In contrast traditional lines patient-derived xenograft (PDX) models, gynecologic accurately mirror genetic mutations specific gene expression profiles tumors. This review provides an overview recent advancements organoid highlighting their contributions understanding disease mechanisms, facilitating advancing precision medicine. It also addresses potential technology, focus on its treatment approaches GCs.

Language: Английский

hPSCs-derived brain organoids for disease modeling, toxicity testing and drug evaluation

Experimental Neurology, Journal Year: 2024, Volume and Issue: 385, P. 115110 - 115110

Published: Dec. 10, 2024

Language: Английский